STUDY OF THE HEPATITIS C VIRUS
IN THE REPUBLIC OF MACEDONIA
Kiprijanovska S1, Sukarova-Stefanovska E1, Noveski P1,
Chalovska V2, Polenakovic M1, Plaseska-Karanfilska D1,*
*Corresponding Author: Professor Dr. Dijana Plaseska-Karanfilska, Research Centre for Genetic
Engineering and Biotechnology “Georgi D. Efremov”, Macedonian Academy of Sciences and Arts, Krste
Misirkov 2, Skopje 1000, Republic of Macedonia; Tel: +389(0)2 3235410; Fax: +389 (0)2 3115434; E-mail:
dijana@manu.edu.mk
page: 67
download article in pdf format
|
|
Abstract
Hepatitis C virus (HCV) is a major public health
problem. It is a leading cause of chronic liver disease
and the most common indication for liver transplantation.
The therapy for eradication of HCV infection
is successful in only 50.0-80.0% of patients and is
highly dependent on the HCV genotype.
Molecular detection and characterization of
HCV in the Republic of Macedonia started in
1990. Since then, more than 4000 samples have
been analyzed at the Research Centre for Genetic
Engineering and Biotechnology (RCGEB) “Georgi
D. Efremov,” Skopje, Republic of Macedonia. The
prevalence of HCV infections in the healthy population
of the Republic of Macedonia was found to
be 0.4%, while it varies between 23.0 and 43.0% in
different at-risk groups of patients.
The prevalence of HCV genotypes, according
to associated risk factors in HCV infected patients
from the Republic of Macedonia, was analyzed. We
found genotype 1 to be predominant in a group of
hemodialysis patients, while genotype 3 was predominant
in intravenous (IV) drug users. Association of six polymorphisms in the
Oligoadenylate synthetase (OASL)-like interferonstimulated
gene with a sustained virological response
was also analyzed. Our preliminary results
suggest that non ancestral alleles in four of the six
studies polymorphisms in OASL gene are associated
with sustained virological response among HCV infected
patients in R. Macedonia.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
